Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury

NCT ID: NCT06410443

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Due to the increasing number and prolonged survival of malignant tumor patients treated with radiotherapy, the complication, such as acute radiation-induced intestinal injury, has become increasingly significant. Glucocorticoids may play a therapeutic role by regulating the inflammatory response in patients with acute radiation-induced intestinal injury. However, the conclusions of related studies were controversial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 60 patients with acute radiation-induced intestinal injury will be enrolled. They will be randomly assigned at a 1:1 ratio into glucocorticoid group and standard treatment group. The primary endpoint is the recovery and improvement of acute radiation-induced intestinal injury. The secondary study endpoints include the recurrence and aggravation of radiation-induced intestinal injury, and adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radiation-Induced Intestinal Injury

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Radiation-Induced Intestinal Injury glucocorticoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glucocorticoids+routine treatment group

Dexamethasone retention enema

Group Type EXPERIMENTAL

Dexamethasone

Intervention Type DRUG

Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.

Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation

Intervention Type DRUG

Treatment according to guideline of radiation-induced intestinal injury.

Routine treatment group

Routine treatment of acute radiation-induced intestinal injury according to the current practice guideline

Group Type ACTIVE_COMPARATOR

Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation

Intervention Type DRUG

Treatment according to guideline of radiation-induced intestinal injury.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.

Intervention Type DRUG

Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation

Treatment according to guideline of radiation-induced intestinal injury.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RHP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Grade II-III acute radiation-induced rectosigmoid injury
2. Signed informed consents
3. Age ≥18 years
4. Rstimated survival time \>1 year

Exclusion Criteria

1. Absolute contraindications to glucocorticoids
2. A history of glucocorticoids treatment within 3 months
3. Inflammatory bowel disease or infectious intestinal disease
4. Recurrence of malignant tumor
5. Colorectal cancer or metastasis
6. Severe heart or lung diseases
7. Recent history of surgery or trauma
8. Poorly controlled hyperglycemia and hypertension
9. Active tuberculosis
10. Ssevere gastrointestinal ulcers
11. Glaucoma
12. Sychiatric diseases
13. Pregnant or lactating
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

General Hospital of Shenyang Military Region

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xingshun Qi

Director of Department of Gastroenterology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xingshun Qi

Role: PRINCIPAL_INVESTIGATOR

The General Hospital of Northern Theater Command

Xiaofeng Liu

Role: PRINCIPAL_INVESTIGATOR

The 960th Hospital of the Chinese People's Liberation Army

Xiaohua Bao

Role: PRINCIPAL_INVESTIGATOR

The 964th Hospital of the Chinese People's Liberation Army

Cheng Bai

Role: PRINCIPAL_INVESTIGATOR

The 967th Hospital of the Chinese People's Liberation Army

Junchen Ge

Role: PRINCIPAL_INVESTIGATOR

The 962rd Hospital of the Chinese People's Liberation Army

Dongshuai Su

Role: PRINCIPAL_INVESTIGATOR

The 963rd Hospital of the Chinese People's Liberation Army

Wenda Xu

Role: PRINCIPAL_INVESTIGATOR

The 81th Group Military Hospital of of the Chinese People's Liberation Army

Ran Jiang

Role: PRINCIPAL_INVESTIGATOR

The 966th Hospital of the Chinese People's Liberation Army

Yumei Hou

Role: PRINCIPAL_INVESTIGATOR

92493 Hospital of the Chinese People's Liberation Army

Hong Dai

Role: PRINCIPAL_INVESTIGATOR

Liaoning Provincial Corps Hospital of the Chinese People's Armed Police

Bingguo Piao

Role: PRINCIPAL_INVESTIGATOR

The 78th Group Military Hospital of the Chinese People's Liberation Army

Yufeng Zhang

Role: PRINCIPAL_INVESTIGATOR

The 79th Group Military Hospital of of the Chinese People's Liberation Army

Lichun Shao

Role: PRINCIPAL_INVESTIGATOR

Air Force Hospital of Northern Theater Command

Haijun Liang

Role: PRINCIPAL_INVESTIGATOR

96605 Hospital of the Chinese People's Liberation Army

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)

Shenyang, Liaoning, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xingshun Qi

Role: CONTACT

Phone: 18909881019

Email: [email protected]

Qianqian Li

Role: CONTACT

Phone: 13940307473

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xingshun Qi, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Kochhar R, Patel F, Dhar A, Sharma SC, Ayyagari S, Aggarwal R, Goenka MK, Gupta BD, Mehta SK. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci. 1991 Jan;36(1):103-7. doi: 10.1007/BF01300096.

Reference Type RESULT
PMID: 1670631 (View on PubMed)

Chen W, Ma Q, Yang L, Zhang L, Zhu J, Lin W. Curative effects of montmorillonite powder combined with dexamethasone on acute radiation enteritis. Am J Transl Res. 2021 Jun 15;13(6):7270-7275. eCollection 2021.

Reference Type RESULT
PMID: 34306492 (View on PubMed)

Li Q, Liu X, Shao L, Bao X, Bai C, Ge J, Su D, Xu W, Jiang R, Mu Z, Dai H, Piao B, Zhang Y, Liang H, Yan Y, Zhang C, Xu X, Chen J, Wang J, Zhang J, Zhang J, Zhang Y, Wang J, Yang Q, Li X, Zhang X, Hou Y, Jiang R, Jin H, Qi X, Wang H. Efficacy and safety of local glucocorticoids for the treatment of acute radiation-induced intestinal injury: protocol of a multicenter randomized controlled trial. Front Pharmacol. 2025 May 30;16:1529977. doi: 10.3389/fphar.2025.1529977. eCollection 2025.

Reference Type DERIVED
PMID: 40520206 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XHNKKY-RII-RCT

Identifier Type: -

Identifier Source: org_study_id